BVF INC IL
Q4 2024 Form 13-F
SAN FRANCISCO, CALIFORNIA
CIK 0001056807
· Institutional investment manager
Consolidated report · includes
1 manager
since Q2 2013
$3.0B Reported Value Total
Reported value
$3.0B
Quarter over quarter
-9.9%
Holdings
53
Top-10 concentration
70.1%
Filing Structure
Reports holdings for
- BVF PARTNERS L P IL · File #028-06770 · since Q2 2013
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Mark N. Lampert
President
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q4 2024 13F record
Q4 2024 13F filing summary
| Period of report | December 31, 2024 |
|---|---|
| Filed | February 14, 2025 |
| Form | 13F-HR |
| Reported value | $3.0B |
| Positions | 53 |
| Change in reported value | -13.7% |
| New positions | 5 |
| Exited positions | 7 |
| Position turnover | 20.0% |
| Top-10 concentration | 70.1% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
44 | $3.9B |
|
Q1 2026 13F
Filed May 15, 2026
|
41 | $3.1B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
41 | $3.0B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
46 | $2.5B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
44 | $2.8B |
|
Q1 2025 13F
Filed May 15, 2025
|
51 | $2.5B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
53 | $3.0B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
55 | $3.4B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
60 | $3.6B |
|
Q1 2024 13F
Filed May 15, 2024
|
62 | $3.6B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
70 | $4.0B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
69 | $3.7B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
67 | $3.6B |
|
Q1 2023 13F
Filed May 15, 2023
|
72 | $2.7B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
78 | $2.4B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
80 | $2.4B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
79 | $2.1B |
|
Q1 2022 13F
Filed May 16, 2022
|
81 | $2.5B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
83 | $2.8B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
75 | $2.6B |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q4 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | $1.1B | 36.25% |
| 2 | KYMR KYMERA THERAPEUTICS INC | $207.7M | 7.04% |
| 3 | RVMD REVOLUTION MEDICINES INC | $182.9M | 6.2% |
| 4 | AXSM AXSOME THERAPEUTICS INC | $117.4M | 3.98% |
| 5 | MIRM MIRUM PHARMACEUTICALS INC | $115.6M | 3.92% |
| 6 | XOMA XOMA ROYALTY CORPORATION | $95.5M | 3.24% |
| 7 | PTGX PROTAGONIST THERAPEUTICS INC | $73.3M | 2.49% |
| 8 | GHRS GH RESEARCH PLC | $72.8M | 2.47% |
| 9 | CGEM CULLINAN THERAPEUTICS INC | $70.0M | 2.37% |
| 10 | ZYME ZYMEWORKS INC | $63.1M | 2.14% |
| 11 | SEPN SEPTERNA INC | $56.2M | 1.9% |
| 12 | TYRA TYRA BIOSCIENCES INC | $54.8M | 1.86% |
| 13 | ACIU AC IMMUNE SA | $52.7M | 1.79% |
| 14 | XNCR XENCOR INC | $52.6M | 1.78% |
| 15 | GPCR STRUCTURE THERAPEUTICS INC | $48.0M | 1.63% |
| 16 | CELC CELCUITY INC | $45.4M | 1.54% |
| 17 | LKFT GALAPAGOS NV | $43.2M | 1.46% |
| 18 | VERV VERVE THERAPEUTICS INC | $38.9M | 1.32% |
| 19 | ANNX ANNEXON INC | $35.9M | 1.22% |
| 20 | AGIO AGIOS PHARMACEUTICALS INC | $35.3M | 1.2% |
Values as reported on the Q4 2024 Form 13F. Every position is in the holdings table below.